Research Article
COVID-19: A Single-Center ICU Experience of the First Wave in the Philippines
| | ICU survivors (n = 54) | ICU nonsurvivors (n = 37) | Significance |
| Demographics | | | | Age (years) | 66 (±15) | 63 (±13) | 0.253 | Gender (% of males) | 61.1% | 64.9% | 0.826 | SAPS-3 | 47 (±13) | 60 (±17) | <0.001 | SARS-CoV-2 status | | | <0.001 | Positive | 9 (16.7%) | 22 (59.5%) | | Negative | 45 (83.3%) | 15 (40.5%) | | Comorbidities | | | | Neurologic | | | 0.003 | Yes | 14 (25.9%) | 1 (2.7%) | | No | 40 (74.1%) | 36 (97.3%) | | Cardiovascular | | | 0.440 | Yes | 44 (81.5%) | 27 (73%) | | No | 10 (18.5%) | 10 (27%) | | Pulmonary | | | 0.821 | Yes | 17 (31.5%) | 13 (35.1%) | | No | 37 (68.5%) | 24 (64.9%) | | Renal | | | 0.039 | Yes | 22 (40.7%) | 7 (18.9%) | | No | 32 (59.3%) | 30 (81.1%) | | Endocrine | | | 0.831 | Yes | 23 (42.6%) | 17 (45.9%) | | No | 31 (57.4%) | 20 (54.1%) | | Autoimmune | | | 0.302 | Yes | 7 (13%) | 2 (5.4%) | | No | 47 (87%) | 35 (94.6%) | | Malignancy | | | 0.344 | Yes | 5 (9.3%) | 6 (16.2%) | | No | 49 (90.7%) | 31 (83.8%) | | Laboratories on ICU admission | | | | Hemoglobin (g/L) | 120 (±30) | 131 (±23) | 0.050 | WBC count (×103/µL) | 12.7 (±10) | 9.5 (±5) | 0.081 | Platelets (×109/L) | 231 (±91) | 232 (±110) | 0.952 | PF ratio | 258 (±145) | 166 (±99) | 0.003 | Lactate (mmol/L) | 2.7 (±2.2) | 2.4 (±1.8) | 0.537 | Treatment strategy | | | | Hydroxychloroquine | | | <0.001 | Yes | 12 (22.2%) | 22 (59.5%) | | No | 42 (77.8%) | 15 (40.5%) | | Tocilizumab | | | 0.008 | Yes | 6 (11.1%) | 13 (35.1%) | | No | 48 (88.9%) | 24 (64.9%) | | Lopinavir/ritonavir | | | 0.017 | Yes | 1 (1.9%) | 6 (16.2%) | | No | 53 (98.1%) | 31 (83.8%) | | CRRT | | | <0.001 | Yes | 8 (14.8%) | 20 (54.1%) | | No | 46 (85.2%) | 17 (45.9%) | | NMBA | | | 0.007 | Yes | 1 (1.9%) | 7 (18.9%) | | No | 53 (98.1%) | 30 (81.1%) | | Prone positioning | | | 0.023 | Yes | 4 (7.4%) | 12 (32.4%) | | No | 50 (92.6%) | 25 (67.6%) | | IVIG | | | 0.564 | Yes | 1 (1.9%) | 2 (5.4%) | | No | 53 (98.1%) | 35 (94.6%) | | HA-330 | | | 0.058 | Yes | 2 (3.7%) | 6 (16.2%) | | No | 52 (96.3%) | 31 (83.6%) | | Intubation | | | <0.001 | Yes | 27 (50%) | 36 (97.3%) | | No | 27 (50%) | 1 (2.7%) | | Others | | | | Number of days intubated | 12 (±8) | 9 (±7) | 0.111 |
|
|